News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
261,383 Results
Type
Article (13925)
Company Profile (299)
Press Release (247159)
Section
Business (79355)
Career Advice (151)
Deals (13188)
Drug Delivery (34)
Drug Development (50318)
Employer Resources (31)
FDA (5680)
Job Trends (5115)
News (144127)
Policy (10019)
Tag
Academia (901)
Alliances (21515)
Alzheimer's disease (750)
Approvals (5654)
Artificial intelligence (67)
Bankruptcy (97)
Best Places to Work (4517)
Biotechnology (245)
Breast cancer (107)
Cancer (856)
Cardiovascular disease (67)
Career advice (132)
CAR-T (68)
Cell therapy (208)
Clinical research (40056)
Collaboration (278)
Compensation (121)
COVID-19 (1005)
C-suite (76)
Cystic fibrosis (66)
Data (960)
Diabetes (81)
Diagnostics (1206)
Earnings (28996)
Events (47156)
Executive appointments (227)
FDA (6024)
Funding (292)
Gene editing (63)
Gene therapy (161)
GLP-1 (306)
Government (1064)
Healthcare (6540)
Infectious disease (1041)
Inflammatory bowel disease (98)
IPO (7192)
Job creations (860)
Job search strategy (127)
Layoffs (186)
Legal (1374)
Lung cancer (123)
Lymphoma (57)
Manufacturing (79)
Medical device (2562)
Medtech (2563)
Mergers & acquisitions (6117)
Metabolic disorders (243)
Neuroscience (987)
NextGen Class of 2024 (2000)
Non-profit (845)
Northern California (1053)
Obesity (134)
Opinion (91)
Parkinson's disease (70)
Patents (59)
People (25064)
Phase I (14118)
Phase II (18625)
Phase III (11799)
Pipeline (358)
Postmarket research (851)
Preclinical (5969)
Radiopharmaceuticals (205)
Rare diseases (196)
Real estate (1409)
Regulatory (8261)
Research institute (930)
Southern California (949)
Startups (1964)
United States (8402)
Vaccines (164)
Weight loss (78)
Date
Last 7 days (434)
Last 30 days (1545)
Last 365 days (20520)
2024 (20074)
2023 (22413)
2022 (26828)
2021 (27807)
2020 (23360)
2019 (16230)
2018 (11746)
2017 (13749)
2016 (11840)
2015 (14350)
2014 (10394)
2013 (7484)
2012 (7532)
2011 (7615)
2010 (7428)
Location
Africa (146)
Asia (16900)
Australia (2848)
California (2389)
Canada (783)
China (193)
Colorado (88)
Connecticut (99)
Europe (36397)
Florida (261)
Georgia (68)
Illinois (145)
Indiana (60)
Kansas (55)
Maryland (320)
Massachusetts (1897)
Michigan (54)
Minnesota (99)
New Jersey (609)
New York (666)
North Carolina (412)
Northern California (1053)
Ohio (81)
Pennsylvania (459)
South America (207)
Southern California (949)
Texas (267)
Washington State (243)
261,383 Results for "cristal therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
Business
Merck Announces Appointment of Cristal N. Downing as Chief Communications & Public Affairs Officer
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that Cristal N. Downing has been appointed chief communications & public affairs officer, a newly created role, effective August 16, 2021.
July 29, 2021
·
4 min read
Regulatory
FDA Warns Applied Therapeutics of ‘Objectionable Conditions’ in Govorestat Study
The agency’s warning letter outlines Applied Therapeutics’ failure to provide adequate information regarding the clinical trial—including a dosing error for govorestat—claims that the company said it had already addressed.
December 4, 2024
·
2 min read
·
Tristan Manalac
Press Releases
NeuroEM Therapeutics(R) Accepted into StartUp Health’s Alzheimer’s Moonshot Community(TM)
September 19, 2024
·
4 min read
Complete response letters
Applied Therapeutics Crashes After FDA Rejection of Rare Disease Drug
After extending its review period to evaluate additional submissions, the FDA ultimately denied Applied Therapeutics’ govorestat for galactosemia, citing “deficiencies” with the application. The biotech plans to meet with the regulator to discuss the best way forward for the drug.
December 2, 2024
·
3 min read
·
Tristan Manalac
Layoffs
Spero Therapeutics to Lay Off 39% of Employees
Following disappointing results for an antibiotic candidate whose development program is now being suspended, Spero Therapeutics is looking to extend its cash runway while it focuses on other assets in its pipeline.
October 30, 2024
·
1 min read
·
Angela Gabriel
Layoffs
Viracta Therapeutics Cuts 42% of Staff as Part of Resource Reprioritization
Following two layoffs in less than three months, Viracta Therapeutics may have around 18 employees left to advance its efforts to bring lead product candidate nana-val to market.
November 7, 2024
·
2 min read
·
Angela Gabriel
Press Releases
Outlook Therapeutics® Announces Executive Leadership Transition
December 3, 2024
·
5 min read
Layoffs
Relay Therapeutics to Lay Off 10% of Workforce
Relay Therapeutics is cutting its workforce to help streamline its research organization as it looks to complete its first large-scale, pivotal clinical trial.
October 4, 2024
·
1 min read
·
Angela Gabriel
Mergers & acquisitions
Novartis Buys Kate Therapeutics, Eyeing $55B CGT Market Opportunity by 2030
Novartis’ up to $1.1 billion acquisition of gene therapy specialist Kate Therapeutics fits with the pharma’s plan to expand its new modality pipeline to ensure long-term business sustainability.
November 21, 2024
·
2 min read
·
Tristan Manalac
1 of 26,139
Next
